101.87
-0.04 (-0.03%)
| 前收盘价格 | 101.90 |
| 收盘价格 | 101.81 |
| 成交量 | 270,214 |
| 平均成交量 (3个月) | 5,293,265 |
| 市值 | 19,330,494,464 |
| 预期市盈率 (P/E Forward) | 185.19 |
| 价格/销量 (P/S) | 6.23 |
| 股市价格/股市净资产 (P/B) | 7.77 |
| 52周波幅 | |
| 利润日期 | 3 Nov 2025 |
| 营业毛利率 | -36.06% |
| 营业利益率 (TTM) | -11.53% |
| 稀释每股收益 (EPS TTM) | -5.53 |
| 季度收入增长率 (YOY) | 10.90% |
| 总债务/股东权益 (D/E MRQ) | 105.93% |
| 流动比率 (MRQ) | 2.73 |
| 营业现金流 (OCF TTM) | 323.66 M |
| 杠杆自由现金流 (LFCF TTM) | 163.08 M |
| 资产报酬率 (ROA TTM) | -1.83% |
| 股东权益报酬率 (ROE TTM) | -36.89% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 看涨 | 看涨 |
| Diagnostics & Research (全球的) | 看涨 | 看涨 | |
| 股票 | Exact Sciences Corporation | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.38 |
|
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.92% |
| 机构持股比例 | 98.89% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 105.00 (Mizuho, 3.08%) | 保留 |
| 105.00 (Evercore ISI Group, 3.08%) | 保留 | |
| 105.00 (Stifel, 3.08%) | 保留 | |
| 105.00 (Canaccord Genuity, 3.08%) | 保留 | |
| 105.00 (Jefferies, 3.08%) | 保留 | |
| 105.00 (Wells Fargo, 3.08%) | 保留 | |
| 105.00 (Barclays, 3.08%) | 保留 | |
| 中 | 105.00 (3.08%) | |
| 低 | 75.00 (Benchmark, -26.37%) | 购买 |
| 75.00 (Guggenheim, -26.37%) | 购买 | |
| 平均值 | 94.46 (-7.27%) | |
| 总计 | 6 购买, 7 保留 | |
| 平均价格@调整类型 | 86.51 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Mizuho | 20 Jan 2026 | 105.00 (3.08%) | 保留 | 102.35 |
| Evercore ISI Group | 05 Jan 2026 | 105.00 (3.08%) | 保留 | 101.61 |
| Stifel | 28 Nov 2025 | 105.00 (3.08%) | 保留 | 101.29 |
| 04 Nov 2025 | 80.00 (-21.46%) | 购买 | 69.59 | |
| Canaccord Genuity | 25 Nov 2025 | 105.00 (3.08%) | 保留 | 101.13 |
| Jefferies | 24 Nov 2025 | 105.00 (3.08%) | 保留 | 101.01 |
| Barclays | 21 Nov 2025 | 105.00 (3.08%) | 保留 | 100.90 |
| 04 Nov 2025 | 77.00 (-24.41%) | 购买 | 69.59 | |
| Wells Fargo | 21 Nov 2025 | 105.00 (3.08%) | 保留 | 100.90 |
| 05 Nov 2025 | 85.00 (-16.56%) | 购买 | 69.63 | |
| Piper Sandler | 11 Nov 2025 | 80.00 (-21.46%) | 购买 | 67.50 |
| BTIG | 04 Nov 2025 | 85.00 (-16.56%) | 购买 | 69.59 |
| Baird | 04 Nov 2025 | 88.00 (-13.61%) | 购买 | 69.59 |
| Benchmark | 04 Nov 2025 | 75.00 (-26.37%) | 购买 | 69.59 |
| Guggenheim | 04 Nov 2025 | 75.00 (-26.37%) | 购买 | 69.59 |
| TD Cowen | 04 Nov 2025 | 90.00 (-11.65%) | 购买 | 69.59 |
| 显示更多 | ||||
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合